** U.S.-listed shares of Israel-based drugmaker Teva Pharmaceutical Industries TEVA.TA, TEVA.N rises 6.6% to $17.32 premarket
** TEVA and partner Biotech Alvotech ALVO.O say the U.S. FDA has accepted for review its marketing application for a biosimilar or close copy of Regeneron's REGN.O Eylea
** Co says AVT06 is a proposed biosimilar of Eylea's 2 milligram dose which is used to treat eye disorders like macular degeneration, macular edema and retinopathy
** Co, ALVO expects regulatory decision for AVT06 by Q4 2025
** Some key patents of Eylea are set to expire in 2027, according to a regulatory filing
** ALVO is also developing AVT29, a biosimilar for Eylea HD, a 8 mg dose of the drug
** Amgen AMGN.O will also make its biosimilar version of Eylea available to patients after a U.S. appeals court rejected REGN's request to block its launch
** In the last 12 months, TEVA has risen 32.4%
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。